Wechselwirkungen · Xenleta
Xenleta 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-144139 · Präparat HOS-099116
(Inhibition of CYP3A4) HIV-ANTIVIRAL AGENTS Efavirenz * Not studied Co-administration of 600 mg once daily Expected ↓ moderate CYP3A Lefamulin inducers may result in (Moderate reduced therapeutic induction of effect of lefamulin and CYP3A4) is contraindicated (see section 4.3). BENZODIAZEPINE BZ1 RECEPTOR ANTAGONIST Zolpidem* Not studied Monitor for adverse 10 mg single dose Expected ↑ reactions during co- Zolpidem administration with (Inhibition of lefamulin. Consider CYP3A4) dosage adjustment of zolpidem#. 6 Medicinal product by therapeutic Effect on areas/possible medicinal Cmax AUC Clinical comments mechanism of product levels interaction GASTRIC ACID SUPPRESSORS/NEUTRALIZERS Omeprazole Not studied No dose adjustment Expected: ↔ Lefamulin required. HERBAL PRODUCTS St. John’s Wort Not studied Co-administration of Expected: ↓ Lefamulin strong CYP3A inducers (Strong induction of may result in reduced CYP3A4) therapeutic effect of lefamulin and is contraindicated (see section 4.3). HMG-COA REDUCTASE INHIBITORS Rosuvastatin Not studied Use with caution. 20 mg single dose Atorvastatin, Lovastatin, Pravastatin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) zolpidem (HOS-086327) efavirenz (HOS-087947) pravastatin (HOS-086306) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-27T10:05:00Z · SHA-256 5734c7cd97e8e3d573c5607510d56959d70dd1959b95f4adae73fc0a0a5dd6b3 · Passage 3ffc1a58bc59dcb4cad998eb13febe4e901d3dfe62b9c34fff0cfbb0509ea582 · Zeichen 7236–9810 im Abschnitt